We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 3 februari 2017

Nature Reviews Urology - Table of Contents alert Volume 14 Issue 2

If you are unable to see the message below, click here to view.

Nature Reviews Urology

Key Advances in Medicine eBook from Nature Reviews - FREE to download!

This essential resource summarizes the groundbreaking clinical and
biomedical discoveries of 2016 and highlights the trends to watch out for in 2017,
making it a must read eBook for anyone with an interest in medical science.

Download for free
February 2017 Volume 14 Number 2
Nature Reviews Urology cover
2015 2-year Impact Factor 5.957
In this issue
Research Highlights
Year in Review

Also this month
 The Movember Collection - In partnership with The Movember Foundation
Recommend to library

Prostate cancer: The genomics of localized disease
Published online: 17 January 2017
p65 | doi:10.1038/nrurol.2017.4


Testicular cancer: HDCT is an effective salvage approach
Published online: 06 December 2016
p66 | doi:10.1038/nrurol.2016.256


Prostate cancer: ERSPC calculator recalibrated for China
Published online: 13 December 2016
p66 | doi:10.1038/nrurol.2016.259


Prostate cancer: Do the maths - modelling tumour growth
Published online: 20 December 2016
p66 | doi:10.1038/nrurol.2016.266


Infection: Siderophore-based vaccine protects against E. coli infection
Published online: 29 November 2016
p67 | doi:10.1038/nrurol.2016.253


Bladder cancer: Atezolizumab: an alternative to cisplatin?
Published online: 29 December 2016
p67 | doi:10.1038/nrurol.2016.271


Prostate cancer: Calcium promotes cancer; vitamin D decelerates
Published online: 06 December 2016
p68 | doi:10.1038/nrurol.2016.257


Infection: Dapivirine ring reduces HIV acquisition
Published online: 20 December 2016
p68 | doi:10.1038/nrurol.2016.263


Nature Reviews Urology
JOBS of the week
Postdoctoral Research Fellow
Boston Children's Hospital
More Science jobs from
Nature Reviews Urology
2017 StratCan Interactive Summer School on Cancer Genomics
Stockholm, Sweden
More science events from
Bladder dysfunction in 2016: New insights into interstitial cystitis and chronic pelvic pain syndromes
Jia-Fong Jhang & Hann-Chorng Kuo
Published online: 29 November 2016
p69 | doi:10.1038/nrurol.2016.249
In 2016, immunohistochemical evidence revealed major differences in the inflammatory characteristics of Hunner and non-Hunner interstitial cystitis/bladder pain syndrome (IC/BPS). Evidence has also emerged that an isomer of testosterone, etio-S, might be a urinary biomarker of IC/BPS. Intravesical botulinum toxin injections became a standard treatment of IC/BPS. Furthermore, the International Continence Society has published a new Standard for Terminology for Chronic Pelvic Pain Syndromes.
Full Text | PDF
Prostate cancer in 2016: Improved outcomes and precision medicine come within reach
Cora N. Sternberg & Himisha Beltran
Published online: 04 January 2017
p71 | doi:10.1038/nrurol.2016.270
2016 was an important year for prostate cancer research. New clinical data highlight the need for personalized treatment across clinical disease states and have changed clinical practice for men with metastatic disease. Molecular studies have characterized tumour heterogeneity and informed biomarker development for advanced disease and research into mechanisms of treatment resistance.
Full Text | PDF
Microbiota in 2016: Associating infection and incontinence with the female urinary microbiota
Linda Brubaker & Alan J. Wolfe
Published online: 04 January 2017
p72 | doi:10.1038/nrurol.2016.262
The discovery and confirmation of the female urinary microbiota in 2012 provided opportunities to improve insight into lower urinary tract disorders in women, including UTI and urgency urinary incontinence. Now, research in 2016 has shown that expanded culture techniques enable improved uropathogen detection and confirm that bacteria detected by culture-independent methods are alive.
Full Text | PDF
Bladder cancer in 2016: News in diagnosis, treatment, and risk group assessment
Richard Zigeuner
Published online: 04 January 2017
p74 | doi:10.1038/nrurol.2016.264
2016 has been a good year for research in non-muscle-invasive bladder cancer. Topics to see progress include risk assessment of patients treated with BCG maintenance, the role of repeat transurethral resection of the bladder (TURB), a prospective study of white-light versus narrow-band imaging, a meta-analysis regarding single instillation chemotherapy, and the effect of the use of fluorescence-guided TURB on progression.
Full Text | PDF
Kidney cancer in 2016: RCC — advances in targeted therapeutics and genomics
W. Marston Linehan & Christopher J. Ricketts
Published online: 29 December 2016
p76 | doi:10.1038/nrurol.2016.260
Recent advances have been exciting in the genomics of and targeted therapeutics for renal cell carcinoma (RCC). New agents have been approved for advanced RCC, a novel agent targeting hypoxia-inducible factor 2[alpha] has shown considerable promise and molecular characterization of papillary RCC provides the foundation for development of targeted therapeutic approaches for this disease.
Full Text | PDF
Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy
Teruyuki Ogawa et al.
Published online: 13 December 2016
p79 | doi:10.1038/nrurol.2016.254
Lower urinary tract symptoms (LUTS) are common comorbidities in patients with Parkinson disease, or multiple system atrophy, and these can have considerable negative effects on patients' quality of life. In this Review, the authors describe the prevalence, diagnosis and management of LUTS in patients with PD or MSA, including the key differences in LUTS between patients with these disorders, which can, in some patients, enable a differential diagnosis.
Abstract | Full Text | PDF
Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer
Michael A. Gorin et al.
Published online: 22 November 2016
p90 | doi:10.1038/nrurol.2016.224
Circulating tumour cells (CTCs) have been studied as biomarkers of a number of urological cancers, although the data are strongest in prostate cancer. CTCs have potential clinical applications in early cancer detection, disease staging, monitoring for recurrence, prognostication, and therapy selection, and might help identify which patients are most likely to respond to androgen-pathway targeted therapies for prostate cancer. In this Review, Gorin and colleagues consider the evidence for a role of CTCs in prostate, bladder, and kidney cancer, and discuss their potential clinical applications.
Abstract | Full Text | PDF
On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer
Hironobu Yamashita et al.
Published online: 29 November 2016
p98 | doi:10.1038/nrurol.2016.239
FOX transcription factors are differentially expressed in bladder cancer subtypes and some are key regulators of embryonic bladder development. Yamashita et al. describe the specific roles of FOX genes and proteins in development and differentiation, and highlight functions in bladder cancer pathogenesis.
Abstract | Full Text | PDF
The current evidence on statin use and prostate cancer prevention: are we there yet?
Mahmoud A. Alfaqih et al.
Published online: 25 October 2016
p107 | doi:10.1038/nrurol.2016.199
Several observational studies support the hypothesis that statin use reduces the risk of advanced prostate cancer. In this Review, the authors discuss molecular mechanisms that might determine this effect, as well as data from clinical studies on associations between statin use and various prostate cancer outcomes, highlighting areas that require further research.
Abstract | Full Text | PDF
Semen quality in the 21st century
Helena E. Virtanen, Niels Jorgensen & Jorma Toppari
Published online: 04 January 2017
p120 | doi:10.1038/nrurol.2016.261
Semen quality in young men has been declining, and shows geographical, as well as temporal, variation. Several aspects of modern life, including lifestyle and environmental factors, stress, and exposure to endocrine disruptors and radiation, could be contributing to these trends. In this Review, the authors describe how semen quality is changing in the 21st century, and consider how we can best identify and avoid the underlying causes.
Abstract | Full Text | PDF
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
*Journal Citation Reports, Thomson, 2008. Nature Reviews Urology was previously published as Nature Clinical Practice Urology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group